NCT04633798

Brief Summary

To compare the effect of IPL combined with lipiflow and IPL combined with meibomian gland massage in treating meibomian gland dysfunction of different degrees ,focusing on effective rate, lasting time and changes of meibomian gland function and morphology.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2020

Shorter than P25 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 20, 2020

Completed
6 months until next milestone

First Posted

Study publicly available on registry

November 18, 2020

Completed
13 days until next milestone

Study Start

First participant enrolled

December 1, 2020

Completed
20 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 21, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 21, 2020

Completed
Last Updated

November 18, 2020

Status Verified

November 1, 2020

Enrollment Period

20 days

First QC Date

May 20, 2020

Last Update Submit

November 16, 2020

Conditions

Outcome Measures

Primary Outcomes (4)

  • ocular surface disease index(OSDI)

    The OSDI is assessed on a scale of 0 to 100,with higher scores representing greater disability

    6 months

  • meibomian gland expressibility score and meibum quality score

    The score is on a scale of 0 to 6.The higher scores, the severity of the meibomian gland function(the highest score is 6 and the lowest score is 0)

    6 months

  • meibomian gland dropout score

    the higher scores, the severity of the meibomian gland morphology(The highest score is 6 and the lowest score is 0)

    6 months

  • Breakup time

    the shorter time, the poorer of the tear film stability

    6 months

Study Arms (2)

IPL/Lipiflow

EXPERIMENTAL

the group in which patients treated with IPL combined with lipiflow

Procedure: IPL/Lipiflow

IPL/MGX

ACTIVE COMPARATOR

the group in which patients treated with IPL combined with meibomian gland massage

Procedure: IPL/MGX

Interventions

IPL/LipiflowPROCEDURE

To treat patients with MGD using intense pulsed light combined with lipiflow

IPL/Lipiflow
IPL/MGXPROCEDURE

To treat patients with MGD using intense pulsed light combined with meibomian gland massage

IPL/MGX

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with meibomian gland dysfunction
  • patients with ocular discomfort
  • skin type:FitzpatricⅠ-Ⅳ

You may not qualify if:

  • patients with acute ocular inflammation
  • eye surgery history in the last 12 months
  • patients who have received IPL or Lipiflow in the last 12 months
  • patients who wear contact lens in last one month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Meibomian Gland Dysfunction

Condition Hierarchy (Ancestors)

Eyelid DiseasesEye Diseases

Study Officials

  • Yan Chen, doctor

    Shanghai aier eys hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 20, 2020

First Posted

November 18, 2020

Study Start

December 1, 2020

Primary Completion

December 21, 2020

Study Completion

December 21, 2020

Last Updated

November 18, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share